Digital Mobile X-Ray Devices Market Attractive Market Opportunities in the by 2026

Future Market Insights, in its latest research, delivers key insights on the factors impacting the global digital mobile X-ray device market. According to the report, demand for digital mobile X-ray devices will continue to be fuelled by applications in orthopaedic- and chest-imaging. These two end-use applications accounted for 60% revenue share of the market in 2016.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-990 

Key Driving Factors

• Increasing emphasis on diagnostic imaging services by various government bodies.
• Increasing geriatric population – according to WHO, global geriatric population will reach 2 billion by 2050
• Rising incidences of orthopaedic diseases and bone injuries – WHO estimates global prevalence of arthritis to between 0.3% and 1%
• Contractual agreements and acquisitions by manufacturers
• Increasing adoption of 3D medical imaging equipment, especially in the field of orthopaedics
• Increase in the number of free standing imaging centers

Key Restraints

• High cost of clinical trials and stringent regulations have remained longstanding challenges for manufacturers
• Lack of inadequate imaging infrastructure in developing countries. High cost associated with initial set up and installation has been identified as a major restraint
• Increasing pressure on the healthcare budget in the U.S. and rising awareness among patients about the potential health impact of radiation

By product type, mobile devices will continue to outsell handheld devices. In 2016, of the US$ 7.67 Bn worth of digital X-ray devices sold, 91.5% were mobile devices. However, owing to their small base size, demand for handheld digital mobile X-ray devices will grow at a higher CAGR than mobile devices.

Hospitals and radiology centers will continue to be the leading end-users of digital mobile X-ray devices globally. These two end-users collectively accounted for nearly 70% revenue share of the market in 2016. According to Future Market Insights’ research, these two end-use sectors will continue to account for the bulk of demand for digital mobile X-ray markets during the forecast period.

Region-wise Analysis and Forecast

• North America is the largest market for digital mobile X-rays globally. Demand for digital mobile X-ray devices in the region is fuelled by strong sales in the U.S.
• North America’s revenue share of the global market was nearly 32% in 2016. Owing to increasing demand in Asia Pacific excluding Japan (APEJ), Latin America, and Japan, North America will witness a slight dip in revenue share over the forecast period.
• APEJ is projected to be the fastest growing market for digital mobile X-ray devices globally. The market in the region is expected to grow on account of high volume demand from China and India.
• The Eastern Europe digital mobile X-ray market will witness slowest growth among all regions.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-990 

Competitive Landscape Analysis

Leading companies in the global digital mobile X-ray devices market are General Electric Healthcare Limited, Siemens AG, Esaote SpA, Hitachi Ltd., Koninklijke Philips N.V, Planmed OY, EOS Imaging, and Toshiba Medical Corporation. These leading companies are eyeing the lucrative APEJ market to capitalise on the growing opportunities. Future Market Insights maintains a positive outlook on the global digital mobile X-ray market, projecting it to grow at 7.1% CAGR through 2026.

Digital Breast Tomosynthesis (DBT) Equipment Market Promising Growth Opportunities over 2016 to 2026

Digital breast tomosynthesis (DBT) or 3-D mammography new installations (includes new equipment and 3-D upgradation) expected to reach 4,547 units in 2016, up from 4,061 units in 2015. In terms of revenues, the global digital breast tomosynthesis equipment market is expected to reach 1,007.6 Mn in 2016, witnessing a year-over-year growth of 13.7%. 

Limitations concerning the flat nature of images achieved through a 2-D full-field digital mammography (FFDM) is influencing end-users to adopt DBT equipment for diagnosis of breast cancers. Digital breast tomosynthesis enables radiologists to analyse abnormalities lucidly, helping improve detection rates while reducing callbacks. In the backdrop of these factors, demand for digital breast tomosynthesis equipment is witnessing an uptick, and the trend is expected to gain further momentum in the future.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1241

Sales of DBTs have remained quite robust in the US in the recent past, making North America the most lucrative market globally. The market in the region is largely dominated by Hologic, Inc. although GE and Siemens Healthineers have also registered their presence by launching innovative DBT products at competitive prices. Total DBT equipment revenues in North America were pegged at 472.8 Mn in 2015, with the U.S. accounting for bulk of revenue share. New equipment installation base in North America is expected to reach 2,327 in 2016, up from 2,066 in 2015.

In addition to North America, digital breast tomosynthesis sales are also growing steadily in Western Europe and APEJ. Revenues in Western Europe are anticipated to grow by 13.4% in 2016, whereas APEJ is expected to increase at 12.2%.

By end-users, hospitals account for higher demand for DBTs vis-à-vis diagnostic centres. Many hospitals are in the process of upgrading their existing mammography machines, owing to which demand for DBT equipment is growing at a steady rate. However, high costs, coupled with lack of awareness can impede adoption rates in both hospitals and diagnostic centres, and slow down the growth of the market globally. Installations of DBTs in hospitals totalled 3,020 in 2015, representing a market value worth 542.8 Mn.

Key players in the global digital breast tomosynthesis equipment market include Hologic Inc., GE Healthcare, Siemens Healthineers, Internazionale Medico Scientifica, Fujifilm, and Planmed Oy. The top 3 players - Hologic, Inc., GE Healthcare, and Siemens Healthineers collectively account for nearly 90% revenue share of the market.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1241

Long-term Outlook: In terms of revenues, the global tomosynthesis equipment market is expected to increase at 13.9% CAGR during the forecast period 2016-2026. Total installations of DBT equipment are anticipated to reach 17,700 units.

Veterinary Vaccines Market to Gain a Stronghold by 2026

Demand for veterinary vaccines is witnessing an increase, as focus shifts from cure to prevention among farm- and pet- owners. The global pet humanisation trend is massively influencing demand for veterinary healthy products and services, and vaccines are riding on the coattails of this trend. The global veterinary vaccines market is anticipated to reach US$ 7.24 Bn in 2016, up from US$ 6.82 Bn in 2015.

Focus on improving food security and mitigating the spread of contagious diseases will continue to fuel demand for veterinary vaccines. Increase in foodborne and zoonotic diseases has adversely affected animal production in the recent past, owing to which emphasis on maintaining health and well-being of animals has gained prominence.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-409

On the basis of product type, attenuated live vaccines will continue to hold the leading revenue share, closely followed by inactivated vaccines. These two product segments accounted for nearly 47% revenue share of the market in 2015, and are expected to dominate global revenues in 2016 as well.

By disease type, foot and mouth disease and anaplasmosis are the two largest segments, collectively accounting for over US$ 2.1 Bn in revenues in 2015. Canine parvovirus is another key disease type, contributing significant revenues to the global market.

Veterinary clinics remain the most prominent distribution channel for veterinary vaccines, and accounted for nearly 40% revenue share of the market in 2015. Veterinary clinics sold US$ 2.74 Bn worth of veterinary vaccines in 2015, and this figure is expected to reach US$ 2.91 Bn in 2016.

By animal type, livestock animals accounted for bulk of the demand for veterinary vaccines in 2015, and the status quo is anticipated to remain unchanged in the future as well. Companion animals are further segmented into canine, avian, and feline, of which, canine segment accounted for the bulk of the revenues in 2015.

North America and Western Europe are the two largest markets for veterinary vaccines, collectively accounting for over 57% revenue share of the market in 2015. The market in North America is dominated by the U.S., which accounted for US$ 1.58 Bn in revenues in 2015. The Canada veterinary vaccines market is expected to surpass US$ 500 Mn in revenues in 2016. Outside of North America, Western Europe and Asia Pacific excluding Japan (APEJ) are the leading markets for veterinary vaccines.

Request for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-409

Key players in the global veterinary vaccines market include Merial, Zoetis, Elanco, Merck & Co. Inc, Boehringer Ingelheim GmbH (BIVI), Bayer Pharma AG, Ceva, Virbac, Diamond Animal Healthcare (Heska) and Indian Immunological Ltd.

India Static Compression Therapy Market Display Significant Growth by 2026

Strong demand from diabetics and geriatric population will continue to drive the growth of the India static compression therapy market in 2016. Demand will also grow on account of rising incidence of venous ulcers and other vein diseases. Compression bandages will continue to outsell compression garments, with the former accounting for a revenue share of over 60% in 2015. Overall, the India static compression therapy market is anticipated to rake in US$ 112 Mn in revenues in 2016.

Retail pharmacies will remain the dominant distribution channel, accounting for over 62% revenue share of the market in 2016. Valued at US$ 63 Mn in 2015, the retail pharmacies distribution channel will grow at 7.4% in terms of revenues to reach US$ 67.6 Mn in revenues in 2016.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-in-1680

Sales of compression therapy products and services are also growing through online channels. Online pharmacies are leveraging on offering doorstep delivery and competitive pricing to appeal to end-users. Sales through online pharmacies totalled US$ 39.9 Mn in 2015, and are expected to grow at 5.5% in 2016 to reach US$ 42.11 Mn.

Several players are anticipated to enter the India static compression therapy market, considering the steady growth that the market is currently experiencing. 3M Co., BSN Medical, Sigvaris AG, and Vissco Healthcare are some of the leading players in the India static compression therapy market.

The key players in the India static compression therapy market are focusing on establishing the distribution channels and creating awareness about the benefits of compression stocks among patients. Coban 2 Lite Compression Systems, Jobst, and Vissco Platinum are some of the well-known static compression therapy products available in the market.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-in-1680

Long-term Outlook: The long-term outlook on the India static compression therapy market is positive, with total revenues expected to increase at a CAGR of 7.2% during the forecast period 2015-2025.

Anti-ageing Products, Services, and Devices Market Highly Favorable to the Growth Rate by 2018-2028

Anti-ageing products and services continue to witness steady growth, with global revenues poised to reach US$ 151.8 Bn in 2016, a growth of 7.7% over 2015. Generation X (born between early 60s to mid-70s) will continue to be the key consumer segment, with global demand from this consumer segment anticipated to reach US$ 66,099.3 Mn by the end of this year. The impact of the global ‘health and wellness’ trend has gained further momentum in 2016, with leading brands incorporating concepts of healthy ageing in their products and services.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1661 

Generation X will continue to remain the largest consumers of anti-ageing products and services, followed by baby boomers in terms of revenue share contribution. This demographic is expected to consume US$ 55.7 Bn worth of anti-ageing products and services in 2016-a y-o-y growth rate of 6.8%.

By products, anti-wrinkle products will continue to be the largest segment, contributing US$ 77.7 Bn to global revenues in 2016. Hair colour will remain the second largest segment, whereas dermal fillers will witness the highest y-o-y growth in 2016 over 2015. Hair restoration treatment will remain the most-after anti-ageing service, representing 43.8% revenue share on the basis of services.

By devices, radio frequency devices will maintain its top position in 2016 as well, representing a revenue share of 64.5%. This segment is expected to witness a year-over-year growth of 11.5% in 2016 and reach US$ 1.2 Bn in revenues. On the other hand, anti-cellulite treatment devices will witness the year-over-year growth in 2016, growing at 19.3% in 2016.

U.S.’s dominance of the global anti-ageing market will continue in 2016, and this in turn, will fuel the growth of the North America anti-ageing market. The region has been the hotbed of advances in cosmetology and dermatology, and has a high proliferation of anti-ageing products and services. The baby boomer and Generation X demographic in North America has been overly receptive to new products and services that mask the signs of ageing. These factors will continue to fuel the anti-ageing market in North America, with total revenues expected to reach US$ 51,987.4 Mn in 2016. The other lucrative markets for anti-ageing products and services are Europe and Asia Pacific.

Access Report with Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1661 

Leading players in the global anti-ageing market include Allergan, Inc., L’Oreal SA, Solta Medical, Inc., Cynosure, Inc.

Specialty Active Pharmaceutical Ingredients (API) Market Will Target Emerging Markets by 2024

The global specialty active pharmaceutical ingredients (API) market is anticipated to record a year-over-year growth rate of 7.9% and reach a market value of US$ 119,513.1 Mn in 2016. Small molecules will continue to account for the leading market revenue share by product type, accounting for over two-thirds share in 2016.

Staggering increase in the manufacturing of HPAPI (high potency API) will continue to influence the adoption of API positively. Popularity of peptide-based drugs and the patent expiry of blockbuster branded drugs in the near future is also expected to boost the growth of the market. However, complex manufacturing guidelines and stringent regulatory processes will continue to pose challenges to widespread adoption.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1719 

By product type, growth of the small molecules segment will be positively impacted by increasing outsourcing of active pharmaceutical ingredients manufacturing from European to Asian countries. In addition, rising preference for HPAPI to treat cancer will play a crucial role in the growth of small molecule segment of the global specialty API market.

Based on the consumption pattern, the outsourced segment will continue to dominate market revenues, accounting for nearly 65% share in 2016. New pharmaceutical companies are increasingly entering the market with authorized and approved HPAPI, but lack of manufacturing facility infrastructure is providing an impetus to the outsourcing trend in terms of manufacturing. This factor is currently more pronounced in U.S.-based companies. Furthermore, the tendency of established pharmaceutical companies to curtail the operational and financial load of HPAPI manufacturing is anticipated to play a key role in elevating the outsourcing segment, boosting the growth of SMEs in the market.

FMI’s report has segmented the global specialty active pharmaceutical ingredient market on the basis of region into North America, Europe, and Rest of the World (ROW). The ROW is the leading region in terms of global revenue share, closely followed by Europe and North America. European API manufacturers are competing on the basis of high quality standards, advanced manufacturing installations, and high purity of intermediates (API), whereas ROW CMOs are focusing on bulk API manufacturing.

The key players in the small molecule active pharmaceutical ingredients segment include Johnson Matthey, Almac, and Siegfried Holding AG, which follow advanced manufacturing technology, premium promotion strategies, and provide a range of development and diagnostic services.

Notable companies in the peptide API segment are PolyPeptide Laboratories, Corden Pharma International GmbH (International Chemical Investors Group), Pepscan Holding, Provence Technologies Group, BCN Peptides S.A., and Senn Chemicals AG. They are characterized on the basis of expertise in development and manufacturing, strong client base, and activity in a wide range of industries.

Access Report with Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1719 

Major HPAPI players in the market are Ash Stevens, Inc., Orion Corporation, Farmhispania Group, S.L., Olon S.p.A., and AmbioPharm, Inc., based on widespread market presence, government approvals, and strong distribution channels.

Platelet Rich Plasma (PRP) Market Set to Record Exponential Growth by 2026

The global platelet rich plasma (PRP) market is projected to witness a year-over-year growth rate of 11.8% in 2016 over 2015 to reach US$ 224.0 Mn in revenues. Increase in the number of patients suffering from orthopaedic injuries and widening application area of PRP in different surgeries is likely to catalyse the market the growth. Use of PRP therapy in treating sports injuries is also anticipated to boost the growth of the market.

By type, pure PRP is likely to dominate product segment in 2016 with the revenue share of about 65%. The segment is also forecast to dominate other application segments through the forecast period. This segment is estimated to witness a year-over-year growth of 11.4% to reach US$ 144.3 Mn in revenues in 2016. Pure PRF/Leukocyte rich PRF segment is projected to register impressive year-over-year growth of 15.5% in 2016.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1722 

By origin, autologous segment will continue to be the prominent segment in 2016, accounting for three fourth of total revenue generated in the year. This segment will witness a year-over-year growth of 11.0% to reach US$ 169.1 Mn in revenues in 2016. Autologous segment among other PRP origins is slated to reflect moderate market performance in 2016, is likely to lose market share to allogenic PRP over next four to five years. Allogenic segment is also projected to register an impressive year-over-year growth of nearly 15% in 2016.

Examining the PRP demand statistics from different surgeries clearly forebodes the dominance of orthopaedic surgery. Currently, orthopaedic surgery is the leading application segment accounting for a revenue share of over 35% in 2016.Orthopaedic surgery is followed by cosmetic surgery, which is estimated to be valued over US$ 50 Mn in 2016. Cosmetic surgery will continue to remain the second-largest application segment, with total revenues expected to reach US$ 59.6 Mn by 2016 end.

In terms of geography, North America, being the advanced market, characterized by early adopters of PRP based therapies. The market in North America is estimated to increase by 11.4% in 2016 to reach very close to US$ 120 Mn. Growth of the market in this region is supported by increasing number of cosmetic and orthopaedic surgeries. Moreover, the region is home to some of the most prominent players operating in the PRP market and hence awareness among patients is also high. Awareness among healthcare community as well as patients is also anticipated to fuel the growth of in North American market.

Adoption of PRP therapy in Asia Pacific is growing at a brisk pace, fuelled by the region’s status as an epicentre of medical tourism. The region has a high geriatric population, and adoption of PRP therapy has witnessed a surge in the recent past. The APAC plasma therapy market is anticipated to increase at a year-on-year growth rate of 16.1% in 2016 to reach US$ 40.5 Mn in revenues.

Access Report with Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1722 

Key players operating in the global platelet rich plasma market are Harvest Technologies Corp., Biomet, Inc., Arthrex, Inc. and Arteriocyte Medical Systems, Inc. Dr. PRP America, Cesca Therapeutics, Inc., and Regen Lab SA.

Saudi Arabia Pharmaceutical Market CAGR Projected to Grow at 9.0% through 2026

The significant rise in lifestyle-related diseases and the developments in healthcare infrastructure are expected to influence the demand for pharmaceuticals in Saudi Arabia. In 2016, the Saudi Arabia pharmaceutical market is anticipated to procure value worth US$ 5,209.5 Mn at a y-o-y growth of 6.0 % over 2015. The mounting demand for branded drug products will continue to incite the growth of the Saudi Arabian pharmaceutical market in 2016.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gc-1733 

The demand for pharmaceuticals in Saudi Arabia is expected to register substantial growth owing to the increasing penetration of health insurance companies and the rising incidence rate of non-communicable diseases. Furthermore, the exceptional rise in the per capita income of Saudi Arabia is also expected to foster the demand for branded pharmaceutical drugs. Another key factor driving the growth of the pharmaceutical market in Saudi Arabia is the country’s strategic move to allow 100% FDI in the pharmaceuticals sector. Although, the shortage of profound indigenous research capacity in the pharmaceutical industry and the delayed registration of drug and medicine patents is expected to limit the expansion of the market in 2016 and beyond.

Based on the product type, the pharmaceutical market in Saudi Arabia is expected to witness an upsurge in the prescription-type branded drug products. In terms of market value, the branded drugs are estimated to reach US$ 2,760.8 Mn by 2016-end. The demand for generic drugs is projected to secure steady growth, attributing to the insisting promotion of generic drug adoption by healthcare insurance providers.

On the basis of the diseases, the pharmaceutical drugs used for treatment of cardiovascular diseases will continue exhibiting robust growth in 2016. The demand for cardiovascular medications will continue to surge due to the prominence of circulatory disorders in Saudi Arabia. Additionally, the rising prevalence of disorders related to body sugar levels is expected to make diabetes a rapidly growing disease-based sub-segment in the Saudi Arabia pharmaceutical market.

The pharmaceutical market in Saudi Arabia is also segmented on the basis of distribution channel, where retail pharmacies will continue to account for 80% market share compared to hospital pharmacies. The westernised modernisation of retail pharmacies in Saudi Arabia has led to the availability of a wide range drugs and medicinal products, thereby attaining a considerable growth in the retail pharmacy sub-segment in 2016 and further.

Access Report with Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gc-1733 

The rising resource potential in Saudi Arabia is projected to positively reform the production environment for pharmaceutical manufacturers. In order to expand the market’s size, structuring alliances with well-established native companies is predicted to be a key strategy for global pharmaceutical leaders. The key players in the Saudi Arabia pharmaceutical market include Novartis AG, SPIMACO, Pfizer Inc., and Glaxosmithkline plc., Jamjoom Pharma,  and Tabuk Pharmaceutical Manufacturing Co. among others.

Industrial Microbiology Market to Significant Growth Foreseen by 2024

The global industrial microbiology market is expected to witness a y-o-y growth of 6.7% in 2016 over 2015 and reach US$ 9.46 Bn in revenues. North America will continue to be the most lucrative market, accounting for over 25% of the market share.

In addition to increase in food consumption, rising emphasis on industrial food safety is predicted to fuel market growth. Wide-ranging applications of industrial microbiology and biotechnology in various verticals, including agriculture, pharmaceuticals, and food & beverages are also expected to play a key role in driving the growth of the market. Consumer preference towards nutraceuticals, increasing automation, and strategic partnerships across the healthcare value chain are other key drivers for industrial microbiology market.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1743 

Manufacturing of sterile products specifically demands higher costs in order to maintain aseptic conditions, which remains an abiding challenge for the market. Growing demand for advanced technology is also expected to hamper market growth.

Apart from applications in fermentation of wine, beer, and cheese, the use of industrial microorganisms in syrup formulation is also gaining traction. Other influential trends include use in bioremediation processes, manufacturing of empty capsules, and preparation of genetically modified food products.

On the basis of product type, the global industrial microbiology market is segmented into reaction consumables, equipment & systems, and laboratory supply. While the reaction consumables segment is expected to dominate the market with over 60% of the total market share in 2016, equipment and systems segment’s revenue share will be over 25%. By test type, sterility testing and microbial limit testing are projected to collectively contribute around 60% to the total market share.

The pharmaceuticals & biotechnology segment will remain the largest end-use segment in the industrial microbiology segment, owing to rising novel drug development practices.

America will remain the largest and fastest growing market due to easier product approval processes. The U.S., a leading market for pharmaceuticals, will continue to dominate the North American market, accounting for over three-fourths revenue shares in 2016. Europe will maintain its position as the second largest market for industrial microbiology.

Thermo Fisher Scientific Inc., and bioMérieux SA remained the two largest players, accounting for a market share of 34.8% in 2015 (with respect to reaction consumables segment & reagent kits). Strong product portfolio, strategic R&D, strong market channels, prominent market presence, and sizeable presence in developing regions remain key strengths of these market leaders. Other leading players in the market include Merck KGaA, Qiagen, Sartorius AG, Bio-Rad Laboratories, Inc., and Becton, Dickinson and Company.

Access Report with Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1743 

Regenerative Medicine Market to Record Sturdy Growth by 2026

The global regenerative medicine (bone and joint) market was valued at US$ 4,254.0 Mn in 2015, and is expected to grow at a year-over-year rate of 13.0% to reach US$ 4,808.9 Mn in 2016. In 2015, North America accounted for the largest revenue share of global regenerative medicine (bone & joints) market, representing a market value of US$ 2,039.8 Mn. Owing to increasing demand for bone and joint reconstructive surgeries and encouraging government initiatives, North America is expected to remain the largest market for regenerative medicine (bone and joint) in 2016. Europe is the second largest market for regenerative medicine, with the region’s high geriatric population fuelling adoption at a robust pace.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1326 

By technology, biomaterials segment accounts for the highest market share globally, owing to favourable reimbursement policies and strong demand for biomaterials. Apart from biomaterials, tissue engineering is the other segment which is quickly gaining traction among end-users, and is projected to witness the highest year-over-year growth among all the technology segments.

On the basis of application, bone graft substitute holds the highest share of the market in terms of value owing to a robust demand of bone graft substitute in orthopaedic treatments. However, complications associated with bone graft substitute can pose challenges to adoption in 2016 and beyond.

While North America and Europe are key to the growth of the regenerative medicine market, rising awareness among healthcare professionals and patients in developing countries of Asia Pacific is expected to open up new opportunities for stakeholders. Favourable government initiatives in growing Asian economies such as China and India has paved the way for regenerative medicine market in the region. Moreover, adoption in developed countries of APAC, such as Japan and South Korea is also fuelling the growth of the market.

Access Report with Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1326 

Key participants in the global regenerative medicine market are: Medtronic, Inc. (INFUSE Bone Graft), DePuy Synthes, Inc. (HEALOS Bone Graft), Orthofix, Inc. (Trinity Evolution), NuVasive, Inc. (Osteocel Plus) and Zimmer Holdings, Inc. (CopiOs Bone Void Filler). The key strategy of these players is to expand globally through distribution agreements, mergers and acquisitions, public-private partnerships and new product development.

Dental Imaging Equipment Market will expand at a moderate CAGR during the forecast period 2016-2024

Increase in the number of cosmetic dental surgeries across the world is expected to supplement the demand for enhanced dental imaging equipment. Valued at US$ 2,088.2 Mn in 2015, the global market for dental imaging equipment is expected to surge at a y-o-y growth rate of 5.1% and reach US$ 2,194.7 Mn in 2016. The high prevalence of dental ailments, such as gingivitis, tooth decay, and dry mouth in Europe, North America and Asia Pacific will continue to be an influencing factor for the growth of the dental imaging equipment market. Increasing awareness of dental hygiene is also a key driver fuelling the demand for advanced dental imaging apparatus.

Lack of skilled professionals and lower lifespan of accessories used in such equipment are anticipated to restrain the global expansion and hamper the growth opportunities for the dental imaging equipment market.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-861 

By product-type, extraoral X-ray system will continue to dominate the market; however, the cone-beam computed tomography (CBCT) imaging product is likely to register rapid growth in terms of value and reach US$ 395.7 Mn in 2016.

By end-use, dental clinics and ambulatory surgical centres will witness higher adoption of dental imaging equipment in 2016 and beyond. In terms of market revenue, the independent dental clinics are expected to grow exponentially and contribute US$ 1,480.5 Mn in the global market. Forensic laboratories and hospitals are also anticipated to be prominent end-users of dental imaging equipment, owing to the pathological and surgical use of dental imaging devices.

Owing to the high adoption of CBCT imaging products in the U.S., North America will continue to remain the largest market for dental imaging equipment globally. Europe and APEJ regions will jointly account for over 40% revenue share in 2016.

Access Report with Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-861 

The key players in the global dental imaging equipment market include Acteon Group, Planmeca Oy, Danaher Corporation, Carestream Health, VAtech Co. Ltd., and Dentsply Sirona, among others. Danaher Corporation is expected to be the utmost dominating company in the global market, owing to the company’s flagship product range of advanced CBCT equipment.

Protein A Resins Market Going to Reach US$ 840.4 Mn by 2026

The global protein A resin market is expected to increase at a y-o-y growth rate of over 7% and reach US$ 380.4 Mn in revenues in 2016. North America, Asia Pacific excluding Japan (APEJ), and Western Europe will collectively account for nearly 70% revenue share of the market in 2016. Increasing process efficiency, growing preference for e-distribution channels and strategic integration of supply chains are some of the major trends impacting the growth of the global protein A resin market.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1720 

The wide range of therapeutic applications of monoclonal antibodies will lead to more research and improved focus on biotechnology sector, resulting into increasing demand for protein A resins. Favourable government policies – in terms of formulation of suitable policies for startups and administration of funding for development of next-gen medical products — are expected to play an important role in driving growth. Development of cost-effective protein A resin is also expected to boost the growth of the market in 2016 and beyond. In contrast, efficacy of alternate purification methods of monoclonal antibodies and high cost (US$ 15,000 – US$ 16,000 per litre) will continue to pose challenges for widespread adoption.

On the basis of product-type, natural protein A resins are expected to outsell recombinant protein A resins. Demand for natural and recombinant protein A resins will be fuelled by the favourable results of the therapeutic uses of monoclonal antibodies. The recombinant protein A resins segment is expected to surpass US$ 135 Mn in revenues in 2016, up from nearly US$ 125 Mn in 2015.

Agarose-based protein A resins will remain the largest segment by matrix type, accounting for over 85% revenue share of the market in 2016. Demand for glass/silica-based and organic polymer-based protein A resins will decline, owing to higher adoption of agarose-based protein A resins.

The antibody purification applications of protein A resins will continue to hold leading market share in 2016, while the immunoprecipitation application segment’s market share is expected to reach 23.5%. Biopharmacuetical manufacturers will remain the prominent end-users of the global protein A resins, followed by clinical research labs and academic institutions.

Increasing number of clinical trials on biologics will continue to have a positive impact on protein A resins market in North America. The demand for protein A resins in APEJ region is expected to increase due to growing research on monoclonal antibodies in India and China.

Access Report with Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1720 

General Electric Company and Thermo Fisher Scientific Inc. are among the leading players in the global protein A resin market. Emerging players Merck Millipore and REPLIGEN CORP., are focusing on increasing market share by strategic collaborations, while expansion of product portfolio in life science and research catalogues remains a key business strategy for Novasep and GenScript.

Liquid Biopsy Market to Receive overwhelming hike in Revenues by 2026

Widespread acceptance of liquid biopsy technique in North America and steady adoption in developing regions is expected to drive global liquid biopsy market revenues. The global market is expected to reach US$ 407 Mn in 2016, up from US$ 351 Mn in 2015. North America will continue to remain the largest market for liquid biopsy, accounting for over 50% share of the global market.

The minimally-invasive nature and economical affordability of liquid biopsy tests will play a key role in bolstering demand globally. FDA approvals for non-invasive diagnostic tests for cancers is expected to have a positive influence on the growth of the market.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1396 

An increasing number of biotechnology and pharmaceutical companies are pushing the demand for liquid biopsy for anti-cancerous drug development. Moreover, oncologists are more inclined toward liquid biopsy for cancer detection. Government funding for R&D and clinical trials for diagnostics, treatment, and prevention are other key factors fuelling adoption of liquid biopsy. In contrast, higher cost of liquid biopsy compared to conventional diagnostic techniques, and low awareness regarding liquid biopsy tests can pose challenges to growth.

By bio marker type, circulating tumour cells (CTCs) segment is expected to form the most attractive market segment, contributing more than 60% of the revenue share to the market. On the basis of the sample type, the segment for blood sample will reflect the highest growth potential, with over 93% of the market share by revenues. However, the urine sample segment is anticipated to witness noticeable growth throughout 2016.

By disease indication, lung cancer segment is expected to dominate the market, in terms of revenues. By end user, cancer institutes are estimated to represent a revenue share of around 38% — significantly higher compared to other end-use segments, such as hospitals, academic institutes, and diagnostic centres.

Some of the key players in the global liquid biopsy market include Genomic Health, Inc., Biocept, Qiagen, Inc., Trovagene, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, and Sysmex Corporation. A majority of key companies are concentrating on mergers, acquisitions, and partnerships; while most of them are prioritising innovative diagnostics and technological upgrades for better penetration in developing regional markets.

Access Report with Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1396